

Inhibition of Membrane-associated Calcium-independent Phospholipase A₂ as a Potential Culprit of Anthracycline Cardiotoxicity¹

Luther Swift, Jane McHowat, and Narine Sarvazyan²

Department of Physiology, Texas Tech University Health Sciences Center, Lubbock, Texas 79430 [L. S., N. S.], and Department of Pathology, St. Louis University School of Medicine, St. Louis, Missouri 63104 [J. M.]

ABSTRACT

Administration of anthracyclines, a family of highly effective anticancer drugs, is associated with a cumulative dose-related cardiomyopathy, the etiology of which remains poorly understood. We have discovered that administration of the anthracyclines leads to a marked inhibition of membrane-associated calcium-independent phospholipase A₂ (iPLA₂) both *in vitro* and *in vivo*. To elucidate the clinical relevance of this effect and to correlate it with known cardiotoxicity of the individual anthracyclines, we have compared four anthracycline analogues: doxorubicin, daunorubicin, idarubicin, and epirubicin for their ability to inhibit iPLA₂. Isolated adult rat cardiomyocytes were treated with each analogue at concentrations of 0.1–100 μM, and PLA₂ activity was assessed in cytosolic and membrane fractions using (16:0, [³H]18:1) plasmalogen in the absence of calcium. For all of the examined analogues, iPLA₂ inhibition was concentration and time dependent, preceded detectable changes in cell viability, and was specific to the membrane-associated enzyme. The degree of iPLA₂ inhibition by equimolar concentrations of epirubicin and idarubicin was significantly less than that of doxorubicin or daunorubicin, which correlates with the reported *in vivo* cardiotoxicity of these drugs. Because membrane iPLA₂ represents the majority of myocardial PLA₂ activity, its inhibition by anthracyclines would critically impair the ability of cardiomyocytes to repair oxidized phospholipids. Indeed, anthracycline-pretreated myocytes become more susceptible to the low-level oxidative stress imposed by repetitive additions of *tert*-butyl peroxide. The results suggest that iPLA₂ inhibition may be the initial step in a chain of events leading to chronic cardiotoxicity of the anthracyclines.

INTRODUCTION

Anthracyclines are powerful anticancer antibiotics, the therapeutic efficiency of which is abridged by the prominent cardiotoxicity of the drugs (1–3). Numerous studies have ascribed the cardiotoxicity of these drugs to specific cellular pathways, including an increase in the formation of free radicals, interference of calcium dynamics, adverse effects on RNA synthesis, and other putative mechanisms (4, 5). Unfortunately, most of these studies have been conducted using exceedingly high concentrations of the drugs, making their relevance to clinical toxicity questionable (1). Moreover, therapeutic interventions, based on the above mechanisms, have had limited success (5). Therefore, our recent findings that membrane-bound iPLA₂³ is markedly inhibited by low, clinically relevant concentrations of DOX both *in vitro* and *in vivo* (6), presents an intriguing possibility that this new phenomenon may underlie cardiotoxicity of anthracyclines. To obtain further support for this hypothesis, we have compared the inhibitory effects of four widely used anthracycline analogues, namely, DOX,

DNR, IDA, and EPI. We argued that if a correlation is observed between the analogue's effect on iPLA₂ activity and clinical indices of cardiotoxicity, it would serve as important evidence that inhibition of this essential myocardial enzyme can be responsible for the deleterious effects of anthracyclines.

MATERIALS AND METHODS

Materials. Collagenase (type II) was purchased from Worthington Biochemical. [³H]arachidonic acid and [³H]oleic acid were purchased from NEN. Clinical grade EPI, IDA (Pharmacia and Upjohn, respectively), DOX, and DNR (both from Bedford Laboratories) were obtained from the Southwest Cancer Center. BEL was a gift from Hoffmann-LaRoche Inc., Nutley, NJ. Gentamicin, MEM (Joklik's modified minimum essential medium), BSA, HEPES, *t*-BOOH, and other reagents were purchased from Sigma.

Preparation of Rat Ventricular Cardiomyocytes. Two-month-old Sprague Dawley rats (200–300 g) were injected i.p. with 500 units/kg sodium heparin. After 20–25 min, the rats were anesthetized i.p. with sodium pentobarbital (45 mg/kg), and the excised hearts were perfused for 10 min with MEM supplemented with 1.25 mM CaCl₂. This was then followed by a 5-min perfusion with a nominally calcium-free MEM, supplemented with 20 mM creatine and 60 mM taurine, and 6–10 min of perfusion with the same medium containing 0.5–1 mg/ml of type II collagenase and 0.1% BSA. The ventricles were then minced and vigorously shaken in the same medium containing 2% BSA. After two washes in collagenase-free medium, the CaCl₂ concentration in the medium was gradually increased to 1.25 mM. With this method, a yield of 5–7 × 10⁶ calcium-tolerant cells per heart was routinely obtained.

Short-Term Treatment of Cells with Anthracyclines. Fifteen-ml tubes containing myocytes in suspension [0.25 × 10⁶ cell/ml Tyrode, supplemented with 10 mM HEPES (pH 7.3)] were gently shaken (0.5 Hz) at room temperature with designated anthracycline concentrations. At the end of the incubation period, cells were washed twice with analogue-free Tyrode and processed for iPLA₂ activity.

Long-Term Treatment of Cells with Anthracyclines. To access cardiotoxicity of the analogues during longer periods, cardiomyocytes were cultured in serum-free conditions, which allows one to maintain the cell's rod-shape phenotype for an extended period (7). Specifically, freshly isolated cells were plated onto 12-mm laminin-covered glass coverslips and were preincubated for 4–5 h in MEM supplemented with 5 mM HEPES, 10 μg/ml gentamicin, 0.1 μg/ml streptomycin, and 0.1 units/ml penicillin. Each slip was then placed in a separate well of a 24-well plate with 1 ml of MEM, followed by the addition of DOX, DNR, IDA, EPI, *t*-BOOH, or BEL to achieve the indicated concentrations. At the end of the incubation period, the total average viability of each slip was evaluated by LDH assay and visual assessment of rod-shaped morphology.

Preparation of Cytosolic and Membrane Fractions. Myocytes were suspended in ice-cold buffer containing: 250 mM sucrose, 10 mM KCl, 10 mM imidazole, 4 mM EDTA, and 2 mM DTT (pH 7.8; PLA₂ assay buffer). To separate membrane and cytosolic fractions, cell sonicates were centrifuged at 14,000 × g for 20 min to remove nuclei and mitochondria, and the supernatant fraction was centrifuged at 100,000 × g for 1 h. The membrane fraction (pellet) was separated from the cytosolic fraction (supernatant) and was resuspended in PLA₂ assay buffer.

Assay of PLA₂ Activity. PLA₂ activity was quantified by incubating the enzyme (8 μg of membrane protein or 200 μg of cytosolic protein) with 100 μM (16:0, [³H]18:1) plasmalogen in assay buffer containing 100 mM Tris, 10% glycerol (pH 7.0), 4 mM EGTA at 37°C for 5 min in a total volume of 200 μl. Synthesis of radiolabeled phospholipid substrate (1-*O*-hexadec-1'-enyl-2-[³H]oleoyl-*sn*-glycero-3-phosphocholine) has been described in detail previ-

Received 2/25/03; revised 4/16/03; accepted 4/29/03.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by National Institutes of Health Grants HL68588 (to J. M.) and HL62419 (to N. S.).

² To whom requests for reprints should be addressed, at Department of Physiology, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430. Phone: (806) 743-2520, Fax: (806) 743-1512; E-mail: narine.sarvazyan@ttuhsc.edu.

³ The abbreviations used are: iPLA₂, calcium-independent phospholipase A₂; DOX, doxorubicin; DNR, daunorubicin; IDA, idarubicin; EPI, epirubicin; BEL, bromoenol lactone; *t*-BOOH, *tert*-butyl hydroperoxide; LDH, lactate dehydrogenase; AIP1, anthracycline-induced PLA₂ inhibition.

ously (8). The reaction was initiated by adding the substrate as a concentrated stock solution in ethanol (5- μ l total volume), which was injected into a total volume of 200- μ l aqueous buffer to achieve a final substrate concentration of 100 μ M. Reactions were terminated by the addition of 100 μ l of butanol. Released radiolabeled fatty acid was isolated by thin-layer chromatography on silica G plates, followed by development in petroleum ether-diethyl ether-acetic acid (70:30:1 v/v/v), and quantification by liquid scintillation spectrometry. The reaction conditions selected resulted in linear reaction velocities with respect to both time and total protein concentration for each substrate examined (9). Protein content was determined by the Lowry method.

Statistics. Statistical comparison of values was performed by Student's *t* test. All of the results are expressed as means \pm SE. Statistical significance was considered to be $P < 0.05$.

RESULTS

Inhibition of iPLA₂ Activity by DNR. Suspensions of freshly isolated myocytes were incubated with 0.1, 1.0, and 10 μ M DNR for either 10 or 30 min and were washed, sonicated, and assessed for iPLA₂ activity in both the membrane and cytosolic fractions. The enzyme activity was measured using (16:0, [³H] 18:1) plas-

menylcholine substrate in the absence of calcium (4 mM EGTA). The membrane iPLA₂ activity was about 20 times higher than of the cytosolic enzyme (4906 \pm 738 versus 206 \pm 28 pmol/mg protein/min). A half-hour incubation of myocytes with micromolar concentrations of the drug resulted in a concentration-dependent decrease in iPLA₂ activity associated with the membrane fraction (Fig. 1B). The degree of enzyme inhibition by higher concentrations of DNR (up to 100 μ M) was only slightly greater than the one produced by 1 μ M. The effect was rapid (Fig. 1C), with a majority of the enzyme activity affected during first 10 min of incubation. Cytosolic iPLA₂ activity was not affected by the DNR treatment (Fig. 1D). For all of the experimental conditions presented in Fig. 1, the viability of the cells remained similar to that of the control samples and did not decrease below 90% of initial viability values.

Inhibition of iPLA₂ Activity by IDA and EPI. Similar sets of experiments were conducted using two other widely used anthracyclines, IDA and EPI (Fig. 2 shows data for IDA only). Analogously to the DOX (6) and DNR data (Fig. 1), only the membrane-associated




Fig. 1. DNR effect on iPLA₂ activity. A, chemical structure of the analogue. B, changes in membrane iPLA₂ activity after 10 and 30 min incubation with 1 μ M DNR. Average from four experiments with each assay run in duplicate. Enzyme activity was measured using (16:0, [³H]18:1) plasmemylcholine in the presence of 4 mM EGTA. *, significant difference at $P < 0.05$ (as compared with pretreatment values). No changes in control samples were observed after 30 min of myocytes incubation in drug-free medium. C, effect of 30-min incubation with increasing DNR concentrations on membrane-associated iPLA₂ activity. **, significant difference at $P < 0.005$, as compared with controls. Average from 10 experiments, with each assay run in duplicate. iPLA₂ activity was measured using (16:0, [³H]18:1) plasmemylcholine in the presence of 4 mM EGTA. D, effect of 30-min incubation with increasing DNR concentrations on cytosolic iPLA₂ activity. Average from 10 experiments, with each assay run in duplicate. iPLA₂ activity was measured using (16:0, [³H]18:1) plasmemylcholine in the presence of 4 mM EGTA.




Fig. 2. IDA effect on iPLA₂ activity. *A*, chemical structure of the analogue. *B*, changes in membrane iPLA₂ activity after 10- and 30-min incubations with 100 μM IDA. Average from four experiments, with each assay run in duplicate. Enzyme activity was measured using (16:0,[³H]18:1) plasménylcholine in the presence of 4 mM EGTA. *, significant difference at $P < 0.05$ (as compared with pretreatment values). No changes in control samples were observed after 30 min of myocytes incubation in drug-free medium. *C*, effect of 30-min incubation with increasing IDA concentrations on membrane-associated iPLA₂ activity. *, significant difference at $P < 0.05$, as compared with controls. Average from seven experiments, with each assay run in duplicate. iPLA₂ activity was measured using (16:0,[³H]18:1) plasménylcholine in the presence of 4 mM EGTA. *D*, effect of 30-min incubation with increasing IDA concentrations on cytosolic iPLA₂ activity. Average from seven experiments, with each assay run in duplicate. iPLA₂ activity was measured using (16:0,[³H]18:1) plasménylcholine in the presence of 4 mM EGTA.

form of the enzyme was affected. The concentrations required to reach statistically significant inhibition of membrane iPLA₂, however, were considerably higher for both IDA and EPI. No effect on cytosolic iPLA₂ activity was observed even at the highest concentrations of the drugs (Fig. 2*D* and data not shown).

Comparative Experiments with Four Analogues. To minimize factors that can compromise direct comparison between different analogues (*e.g.*, inherent differences between animals, variability between PLA₂ assays, quality of myocyte preparation, and so forth) we conducted a set of experiments in which all four of the anthracyclines were tested simultaneously using the cardiomyocyte preparation from the same rat. These experiments used a low, clinically relevant concentration of the analogues (1 μM) and confirmed that the inhibitory effect on iPLA₂ activity exhibited by DNR is similar to that with DOX, whereas EPI and IDA are less effective at inhibiting the enzyme (Fig. 3). Therefore, in respect to their ability to affect membrane-associated iPLA₂, the anthracyclines can be ranked in the following order: DOX~DNR>EPI>IDA. To compare these results with previous studies on cardiotoxicity of these analogues, we have compiled data from previously published *in vitro* and *in vivo* studies (Table 1). The data revealed that the ranking of analogues based on their ability to inhibit iPLA₂ correlates well with clinical cardiotoxicity of these

drugs. It has also been suggested that no direct relationship exists between the ability of individual anthracyclines to inhibit iPLA₂ and acute *in vitro* toxicity of the drug. The next series of experiments tested this assumption directly.




Fig. 3. Comparative effect of analogues on iPLA₂ activity. Cardiomyocytes from the same preparation were incubated for 30 min with each analogue (1 μM). Enzyme activity was assayed using (16:0,[³H]18:1) plasménylcholine in the presence of 4 mM EGTA. Experiment was repeated using four different animals.

Table 1 Comparative analogues cardiotoxicity in different models

Studies	Pecking order more>less toxic	Cardiotoxicity index	Model	Concentrations
<i>In vitro</i> studies using subcellular fractions				
Vile and Winterbourn, 1989 (37)	DNR>DOX EPI	Lipid peroxidation	Rat microsomes	10–60 μ M
Gervasi <i>et al.</i> , 1990 (20)	IDA EPI DOX DNR IDA>EPI>DOX>DNR	NADPH-dependent superoxide production Superoxide formation by mitochondrial NADH-dehydrogenase	Rat sarcosomes Commercial enzyme	10–300 μ M
Maliszka <i>et al.</i> , 1996 (21)	IDA>DOX>DNR>EPI	Semiquinone radical formation (EPR) ^a	CHO cells	3 mM
Tokarska-Schlattner <i>et al.</i> , 2002 (38)	IDA>DOX>DNR	Inhibition of human mitochondrial creatine kinase activity	Purified protein	5–750 μ M
<i>In vitro</i> studies using isolated myocytes or isolated hearts				
Shirhatti <i>et al.</i> , 1986 (22)	IDA>DNR>EPI>DOX	IC ₅₀ based on LDH release	Neonatal rat myocytes	20–200 μ M
Dorr <i>et al.</i> , 1988 (39)	IDA>DOX>DNR	IC ₅₀ for ATP:protein ratio	Neonatal rat myocytes	1.7–17 μ M
Singh <i>et al.</i> , 1989 (23)	IDA>EPI>DNR>DOX IDA>DNR DOX>EPI	LDH release ATP levels	Neonatal rat myocytes	0.11–10 μ M
Chan <i>et al.</i> , 1996 (40)	EPI=IDA	Contractility (shortening)	Adult cultured myocytes	10 μ M
Vidal <i>et al.</i> , 1996 (41)	DNR>DOX	ATP production	Adult myocytes	100–800 μ M
Pouna <i>et al.</i> , 1995 (42)	EPI>DOX	Contractility and compliance	Isolated rat heart	10 μ M
Chen <i>et al.</i> , 1987 (43)	IDA>EPI>DOX	Cardiac function (work)	Isolated rat heart	26 μ M
<i>In vivo</i> animal studies				
Arcamone, 1985 (44)	DOX>EPI>IDA	Cardiac function	Mice	
Yeung <i>et al.</i> , 1989 (45)	DOX>EPI	Cardiac output	Rat, i.p. injection	Single dose, follow-up 4–20 wk
Pouna <i>et al.</i> , 1996 (46)	DOX>EPI>DNR	Cardiac function (dP/dt)	Rat, i.p. injection for 12 days	3 mg/kg/day, every other day
Platel <i>et al.</i> , 1999 (47)	DOX>IDA	Cardiac function (dP/dt)	Rat, i.v. injection every other day for 11 days	DOX 1–3 mg/kg/day IDA 0.5–1 mg/kg/day
Platel <i>et al.</i> , 2000 (48)	DOX>EPI	Cardiac function (dP/dt)	Rat, i.v. injection every other day for 11 days	3 mg/kg/day
Clinical trials/human data				
Gilladoga <i>et al.</i> , 1976 (49)	DOX>DNR	Electrocardiogram changes, incidence of congestive heart failure	Pediatric patients	
Bontenbal <i>et al.</i> , 1998 (50)	DOX>EPI	Incidence of congestive heart failure	Breast cancer patients	
Weiss, 1992 (12)	DOX>EPI DOX>IDA	Overview of randomized Phase III clinical trials	Breast cancer patients	

^a EPR, electron paramagnetic resonance; CHO, Chinese hamster ovary; dP/dt, first derivative of left ventricular pressure used as an index of contractility.

Acute Toxicity of Anthracyclines at Concentrations Exceeding the Clinical Range. Treatment of myocytes with clinically relevant anthracycline concentrations (1–5 μ M for up to 60 h) did not lead to any detectable cell damage (data not shown). Indices of cell necrosis (both morphological and biochemical) become apparent only when cells were exposed to 20- μ M concentrations of the analogues for at least 24 h (Fig. 4). The descending order of acute toxicity of the drugs (IDA>DNR>EPI>DOX) in these experiments was in agreement with *in vitro* data obtained by others (10) but has little correlation with clinical studies (Table 1). Notably, the acute toxicity of the drugs had no correlation with the ability of a particular analogue to inhibit membrane iPLA₂ (compare Figs. 3 and 4).

Anthracyclines and Myocyte Susceptibility to Low-Level Oxidative Stress. Acute cardiomyocyte damage (observed at anthracycline concentrations exceeding clinical range by 10–100-fold) appears to have little relevance to the chronic deleterious effects of these drugs on a patient's heart (1, 2). In contrast, we believe that decreased iPLA₂ activity can be clinically relevant and can lead to a slow deterioration of the cardiac function. Specifically, we hypothesize that because of the essential role of iPLA₂ enzyme in the detoxification of lipid peroxides (6), anthracycline treatment renders cardiomyocytes more susceptible to an oxidative stress. The next series of experiments tested this assumption directly. The cells were pretreated with DOX for 30 min and then were exposed to a low, subtoxic dose of t-BOOH (0.1–5 μ M). The treatment was repeated every 12 h for a total of 48 h. Although selected concentrations of either t-BOOH or anthracycline alone were not toxic to the cells during the 48-h protocol, the combined anthracycline/t-BOOH treatment proved lethal (Fig. 5A). To obtain further evidence that such an effect can be a consequence of iPLA₂ inhibition, we conducted a similar set of experiments substituting DOX with iPLA₂ inhibitor BEL. BEL by itself did not affect myocyte viability, but it markedly augmented susceptibility to t-BOOH-imposed oxidative stress (Fig. 5B).

DISCUSSION

The most dangerous adverse effect that limits therapeutic potency of anthracyclines is their chronic cardiotoxicity. The latter is characterized by progressive left-ventricular dysfunction and congestive heart failure, the risk of which increases precipitously after cumulative doses exceed critical values established for each of its analogues (11, 12). Clinical practice reveals considerable variation in the individual susceptibility to the cardiotoxic effects of these drugs (2). Unfortunately, no specific biochemical, molecular, or genetic markers are currently available to predict an individual patient's susceptibility so that the clinician could tailor anthracycline chemotherapy to minimize its cardiac side-effects. Absence of such markers, as well as the failure of most protocols based on existent hypotheses of anthracycline cardiotoxicity to prevent cardiac dysfunction in clinical settings (5), is largely attributable to an inadequacy of *in vitro* models of anthracycline cardiotoxicity. Specifically, although some pathways have been confirmed on a whole animal level (13–16), the majority of adverse effects exhibited by DOX and its analogues have been studied using sarcolemmal vesicles, mitochondria, isolated cardiomyocytes, or heart slices (reviewed in Refs. 1 and 4) and Table 1). Because of the short-term viability of these preparations, exceedingly high concentrations of the drugs (usually 10–800 μ M versus peak plasma values of 1–5 μ M) must be used to detect significant changes. The reported effects, therefore, reflect the acute cell injury rather than the chronic toxicity of the drug. The only *in vitro* model that allows somewhat extended treatment (1–2 weeks) is cultured neonatal cardiomyocytes (17, 18). Unfortunately, marked differences between neonatal cells and adult cardiac tissue, on a transcriptional, biochemical, and structural level, makes extrapolation of these data to a clinical setting questionable (19).

The discrepancy between *in vitro* data and the results of clinical trials has been noted before (1, 12) and is evident when one briefly




Fig. 4. Acute toxicity of high anthracycline concentrations. Cardiomyocytes in short-term primary cultures were incubated with each analogue (20 μ M), and indices of cell viability were assessed at 24 h and 60 h. The data are the means from triplicate experiments for the control and analogue-treated samples. *, $P < 0.05$; **, $P < 0.005$ (versus control samples). *A*, mortality as determined by the release of LDH into the medium after 24-h incubation. *Insert (gray)*, shows corresponding measurements of cell viability using rod-shaped morphology. *B* mortality as determined by the release of LDH into the medium after 60-h incubation. *Insert (gray)* shows corresponding measurements of cell viability using rod-shaped morphology.

surveys comparative studies on the cardiotoxicity of the analogues (Table 1). Specifically, IDA has been shown to be more potent in stimulating superoxide formation by mitochondrial NADH-dehydrogenase (20), increasing the rate of semiquinone formation (21), or damaging both adult and neonatal cardiac cells (22, 23). At the same time clinical trials report that cardiac side effects of IDA are much less pronounced than those of DOX, especially at equimolar concentrations (12, 24). Similar discordance is evident for EPI treatment (Table 1). Notably, differences in the pharmacokinetics of the analogues and cardiac accumulation do not explain the discrepancies between *in vivo* and *in vitro* data (1, 12).

Therefore, the correlation between the AIPI observed in this study (Figs. 1–3) and clinical cardiotoxicity of anthracyclines (Table 1) is particularly intriguing. Notably, acute injury to the cells caused by the application of 20 μ M DOX, DNR, EPI, or IDA (Fig. 4) was in accordance with both the partition coefficient and cellular intake of the drug (22). Yet, the loss of viability did not correlate with AIPI (Figs. 3 and 4). Thus, we believe that AIPI is not a major cause of acute cell necrosis elicited by high anthracycline concentrations. In fact, our previous studies have shown that a similar degree of iPLA₂ inhibition attained by the exposure to iPLA₂ inhibitor BEL, did not

affect myocyte viability (25). Conversely, we suggest that AIPI may be responsible for chronic toxicity of these drugs via an impairment of oxidized phospholipids recycling and the slow, accumulative changes in membrane composition and the redox status of the cell. One must take into account that (a) oxidized *sn*-2 fatty acyl groups must first be hydrolyzed by PLA₂ to be repaired by cytosolic glutathione peroxidase [followed by reacylation of the phospholipids by CoA-dependent acyltransferase, and CoA-independent transacylase (26)]; and (b) that membrane iPLA₂ accounts for the majority of PLA₂ activity in the heart (27). Therefore, as suggested in Fig. 6, in cardiac muscle, the anthracyclines may not only augment free radical formation but also disable the repair process.

This hypothesis was further supported by our experiments in which anthracycline-treated cells were exposed to low, subtoxic concentrations of t-BOOH (Fig. 5). The data has revealed that combined DOX/t-BOOH treatment is substantially more toxic to the cells, presumably because of the impaired ability on the part of the myocyte to repair oxidized phospholipids (Fig. 5A). One may argue, however, that a DOX-mediated increase in free radicals simply adds to t-BOOH-induced oxidative stress. However, substitution of DOX with the iPLA₂ inhibitor BEL had the equivalent effect [in cardiomyocytes, the activities of other PLA₂s, e.g., secretory sPLA₂ and Ca²⁺-dependent cPLA₂, are insignificant as compared with those of iPLA₂ (27)].

The suggested pathway through which AIPI may lead to anthracycline cardiotoxicity is depicted in Fig. 6. It allows one to reconcile several apparently contradictory results while incorporating existing free-radical hypotheses of anthracycline cardiotoxicity. First, it helps




Fig. 5. Potentiation of t-BOOH toxicity by DOX and BEL. *A*, cardiomyocytes in short-term primary cultures were pretreated with 10 μ M DOX for 30 min before each t-BOOH application. t-BOOH additions were made every 12 h, and the viability of the cells was assessed at the end of the 48-h protocol using a LDH assay. Values represent mean of four separate preparations. *B*, cardiomyocytes in short-term primary cultures were pretreated with 10 μ M BEL for 30 min before each t-BOOH application. t-BOOH additions were made every 12 h, and the viability of the cells was assessed at the end of the 48-h protocol using LDH assay. Values represent mean of four separate preparations.




Fig. 6. Proposed link between anthracycline-induced iPLA₂ inhibition, lipid peroxidation, and chronic damage to myocardium. GPX, glutathione peroxidase; GSH, reduced glutathione; PHGPX, phospholipid GPX; ROS, reactive oxygen species.

to explain how anthracyclines can lead to a measurable lipid peroxidation (28), whereas no significant increases in free-radical formation have been detected at a low micromolar range (21, 29). Secondly, AIPI could explain decreased circulating levels of conjugated dienes and hydroperoxides shown to occur after i.v. administration of DOX to cancer patients (30). The effect (originally ascribed to “paradoxical” inhibition of cardiac lipid peroxidation) is likely to be a direct manifestation of phospholipase inhibition, which decreases the release of conjugated dienes and hydroperoxides from oxidized cardiac membranes. The mechanism shown in Fig. 6 also adds a new aspect to the crucial role of glutathione peroxidases in prevention of anthracycline cardiotoxicity (31). Notably, in the cardiac muscle, the activity of membrane-bound phospholipid glutathione peroxidase [which does not require PLA₂ to reduce oxidized fatty acids (32)] is 100 times lower than the activity of cytosolic glutathione peroxidase (26, 33). Furthermore, several studies have reported a loss of glutathione peroxidase activity in the hearts of anthracycline-treated animals (34–36), suggesting further weakening of the repair cycle in cardiac tissue.

The ability of anthracyclines to inhibit iPLA₂ allows one to suggest that at least some of the drugs’ anticancer effects may come through the inhibition of this enzyme and/or that iPLA₂ inhibitors might have anticancer properties. This intriguing possibility requires further investigation and was not addressed in the present study.

In summary, using isolated rat cardiomyocytes, we have shown for the first time that (a) DNR, EPI, and IDA inhibit iPLA₂ activity in a time- and concentration-dependent manner; (b) these anthracyclines affect activity of the membrane-associated enzyme, whereas no detectable changes occur in the cytosolic fraction; (c) the degree of iPLA₂ inhibition by a particulate analogue is not associated with the drugs’ intracellular accumulation or acute *in vitro* toxicity, but correlates with reported *in vivo* cardiotoxicity of these drugs; and (d) pretreatment with anthracyclines renders cardiomyocytes more susceptible to oxidative stress.

Overall, the data strongly support our original hypothesis that anthracycline-induced iPLA₂ inhibition is involved in the chronic cardiotoxicity of these drugs.

ACKNOWLEDGMENTS

We thank Pamela Kell and Joseph Ugorji for technical assistance, and we are grateful to Dr. Ara Arutunyan for invaluable discussions.

REFERENCES

- Olson, R. D., and Mushlin, P. S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. *FASEB J.*, *4*: 3076–3086, 1990.
- Jain, D. Cardiotoxicity of doxorubicin and other anthracycline derivatives. *J. Nucl. Cardiol.*, *7*: 53–62, 2000.
- Hortobagyi, G. N. Anthracyclines in the treatment of cancer. An overview. *Drugs*, *54* (Suppl. 4): 1–7, 1997.
- Singal, P. K., and Iliskovic, N. Doxorubicin-induced cardiomyopathy. *N. Engl. J. Med.*, *339*: 900–905, 1998.
- Dorr, R. T. Cytoprotective agents for anthracyclines. *Semin. Oncol.*, *23*: 23–34, 1996.
- McHowat, J., Swift, L. M., Arutunyan, A., and Sarvazyan, N. Clinical concentrations of doxorubicin inhibit activity of myocardial membrane-associated, calcium-independent phospholipase A₂. *Cancer Res.*, *61*: 4024–4029, 2001.
- Piper, H. M., Jacobson, S. L., and Schwartz, P. Determinants of cardiomyocyte development in long-term primary culture. *J. Mol. Cell. Cardiol.*, *20*: 825–835, 1988.
- McHowat, J., and Creer, M. H. Lysophosphatidylcholine accumulation in cardiomyocytes requires thrombin activation of Ca²⁺-independent PLA₂. *Am. J. Physiol.*, *272*: H1972–H1980, 1997.
- McHowat, J., Liu, S., and Creer, M. H. Selective hydrolysis of plasmalogen phospholipids by Ca²⁺-independent PLA₂ in hypoxic ventricular myocytes. *Am. J. Physiol.*, *274*: C1727–C1737, 1998.
- Andersson, B. S., Eksborg, S., Vidal, R. F., Sundberg, M., and Carlberg, M. Anthraquinone-induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes. *Toxicology*, *135*: 11–20, 1999.
- Keefe, D. L. Anthracycline-induced cardiomyopathy. *Semin. Oncol.*, *28*: 2–7, 2001.
- Weiss, R. B. The anthracyclines: will we ever find a better doxorubicin? *Semin. Oncol.*, *19*: 670–686, 1992.
- Thompson, R. T., Marsh, G. D., Butland, T., Sprague, C., Sanford, S. E., Peemoeller, H., Driedger, A. A., and Inch, W. R. An *in vivo* animal model to study chronic Adriamycin cardiotoxicity: a P-31 nuclear magnetic resonance spectroscopy investigation. *In Vivo*, *5*: 13–16, 1991.
- Iliskovic, N., Panagia, V., Slezak, J., Kumar, D., Li, T., and Singal, P. K. Adriamycin depresses *in vivo* and *in vitro* phosphatidylethanolamine *N*-methylation in rat heart sarcolemma. *Mol. Cell. Biochem.*, *176*: 235–240, 1997.
- Gambliel, H. A., Burke, B. E., Cusack, B. J., Walsh, G. M., Zhang, Y. L., Mushlin, P. S., and Olson, R. D. Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. *Biochem. Biophys. Res. Commun.*, *291*: 433–438, 2002.
- Boucek, R. J., Jr., Miracle, A., Anderson, M., Engelman, R., Atkinson, J., and Dodd, D. A. Persistent effects of doxorubicin on cardiac gene expression. *J. Mol. Cell. Cardiol.*, *31*: 1435–1446, 1999.
- Jeyaseelan, R., Poizat, C., Wu, H. Y., and Kedes, L. Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. *J. Biol. Chem.*, *272*: 5828–5832, 1997.
- Ito, H., Miller, S. C., Billingham, M. E., Akimoto, H., Torti, S. V., Wade, R., Gahlmann, R., Lyons, G., Kedes, L., and Torti, F. M. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells *in vivo* and *in vitro*. *Proc. Natl. Acad. Sci. USA*, *87*: 4275–4279, 1990.
- Burke, B. E., Mushlin, P. S., Cusack, B. J., Olson, S. J., Gambliel, H. A., and Olson, R. D. Decreased sensitivity of neonatal rabbit sarcoplasmic reticulum to anthracycline cardiotoxicity. *Cardiovasc. Toxicol.*, *2*: 41–51, 2002.
- Gervasi, P. G., Agrillo, M. R., Lippi, A., Bernardini, N., Danesi, R., and Del Tacca, M. Superoxide anion production by doxorubicin analogs in heart sarcosomes and by mitochondrial NADH dehydrogenase. *Res. Commun. Chem. Pathol. Pharmacol.*, *67*: 101–115, 1990.
- Malisza, K. L., McIntosh, A. R., Sveinson, S. E., and Hasinoff, B. B. Semiquinone free radical formation by daunorubicin aglycone incorporated into the cellular membranes of intact Chinese hamster ovary cells. *Free Radic. Res.*, *24*: 9–18, 1996.
- Shirhatti, V., George, M., Chenery, R., and Krishna, G. Structural requirements for inducing cardiotoxicity by anthracycline antibiotics: studies with neonatal rat cardiac myocytes in culture. *Toxicol. Appl. Pharmacol.*, *84*: 173–191, 1986.
- Singh, Y., Ulrich, L., Katz, D., Bowen, P., and Krishna, G. Structural requirements for anthracycline-induced cardiotoxicity and antitumor effects. *Toxicol. Appl. Pharmacol.*, *100*: 9–23, 1989.
- Weiss, R. B., Sarosy, G., Clagett-Carr, K., Russo, M., and Leyland-Jones, B. Anthracycline analogs: the past, present, and future. *Cancer Chemother. Pharmacol.*, *18*: 185–197, 1986.
- McHowat, J., Swift, L. M., and Sarvazyan, N. Oxidant-induced inhibition of myocardial calcium-independent phospholipase a. *Cardiovasc. Toxicol.*, *1*: 309–316, 2001.
- Brigelius-Flohe, R. Tissue-specific functions of individual glutathione peroxidases. *Free Radic. Biol. Med.*, *27*: 951–965, 1999.
- McHowat, J., and Creer, M. H. Comparative roles of phospholipase A₂ isoforms in cardiovascular pathophysiology. *Cardiovasc. Toxicol.*, *1*: 253–265, 2001.
- Thayer, W. S. Serum lipid peroxides in rats treated chronically with Adriamycin. *Biochem. Pharmacol.*, *33*: 2259–2263, 1984.
- Sarvazyan, N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. *Am. J. Physiol.*, *271*: H2079–2085, 1996.
- Minotti, G., Mancuso, C., Frustaci, A., Mordente, A., Santini, S. A., Calafiore, A. M., Liberi, G., and Gentiloni, N. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity. *J. Clin. Invest.*, *98*: 650–661, 1996.
- Doroshov, J. H., Akman, S., Chu, F. F., and Esworthy, S. Role of the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer quinones. *Pharmacol. Ther.*, *47*: 359–370, 1990.

32. Thomas, J. P., Maiorino, M., Ursini, F., and Girotti, A. W. Protective action of phospholipid hydroperoxide glutathione peroxidase against membrane-damaging lipid peroxidation. *In situ* reduction of phospholipid and cholesterol hydroperoxides. *J. Biol. Chem.*, *265*: 454–461, 1990.
33. Bermano, G., Nicol, F., Dyer, J. A., Sunde, R. A., Beckett, G. J., Arthur, J. R., and Hesketh, J. E. Tissue-specific regulation of selenoenzyme gene expression during selenium deficiency in rats. *Biochem. J.*, *311*: 425–430, 1995.
34. Doroshov, J. H. Glutathione peroxidase and oxidative stress. *Toxicol. Lett.*, *82–83*: 395–398, 1995.
35. Nakano, E., Takeshige, K., Toshima, Y., Tokunaga, K., and Minakami, S. Oxidative damage in selenium deficient hearts on perfusion with Adriamycin: protective role of glutathione peroxidase system. *Cardiovasc. Res.*, *23*: 498–504, 1989.
36. Gustafson, D. L., Swanson, J. D., and Pritsos, C. A. Modulation of glutathione and glutathione dependent antioxidant enzymes in mouse heart following doxorubicin therapy. *Free Radic. Res. Commun.*, *19*: 111–120, 1993.
37. Vile, G. F., and Winterbourn, C. C. Microsomal lipid peroxidation induced by anthracycline, epirubicin, daunorubicin and mitoxantrone: a comparative study. *Cancer Chemother. Pharmacol.*, *24*: 105–108, 1989.
38. Tokarska-Schlattner, M., Wallimann, T., and Schlattner, U. Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. *Mol. Pharmacol.*, *61*: 516–523, 2002.
39. Dorr, R. T., Bozak, K. A., Shipp, N. G., Hendrix, M., Alberts, D. S., and Ahmann, F. *In vitro* rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios. *Cancer Res.*, *48*: 5222–5227, 1988.
40. Chan, E. M., Thomas, M. J., Bandy, B., and Tibbits, G. F. Effects of doxorubicin, 4'-epirubicin, and antioxidant enzymes on the contractility of isolated cardiomyocytes. *Can. J. Physiol. Pharmacol.*, *74*: 904–910, 1996.
41. Vidal, R. F., Eksborg, S., Sundberg, M., Carlberg, M., Elfsson, B., and Andersson, B. S. Doxorubicin- and daunorubicin-induced energy deprivation and nucleotide degradation in isolated cardiomyocytes. *Toxicology*, *114*: 1–10, 1996.
42. Pouna, P., Bonoron-Adele, S., Gouverneur, G., Tariosse, L., Besse, P., and Robert, J. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin. *Cancer Chemother. Pharmacol.*, *35*: 257–261, 1995.
43. Chen, Z. M., Colombo, T., Conforti, L., Grazia Donelli, M., Fiedorowicz, R. J., Marchi, S., Paolini, A., Riva, E., Zuanetti, G., and Latini, R. Effects of three new anthracyclines and doxorubicin on the rat isolated heart. *J. Pharm. Pharmacol.*, *39*: 947–950, 1987.
44. Arcamone, F. Properties of antitumor anthracyclines and new developments in their application: Cain Memorial Award lecture. *Cancer Res.*, *45*: 5995–5999, 1985.
45. Yeung, T. K., Simmonds, R. H., and Hopewell, J. W. A functional assessment of the relative cardiotoxicity of Adriamycin and epirubicin in the rat. *Radiother. Oncol.*, *15*: 275–284, 1989.
46. Pouna, P., Bonoron-Adele, S., Gouverneur, G., Tariosse, L., Besse, P., and Robert, J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. *Br. J. Pharmacol.*, *117*: 1593–1599, 1996.
47. Platel, D., Pouna, P., Bonoron-Adele, S., and Robert, J. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. *Anticancer Drugs*, *10*: 671–676, 1999.
48. Platel, D., Pouna, P., Bonoron-Adele, S., and Robert, J. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart. *Toxicol. Appl. Pharmacol.*, *163*: 135–140, 2000.
49. Gilladoga, A. C., Manuel, C., Tan, C. T., Wollner, N., Sternberg, S. S., and Murphy, M. L. The cardiotoxicity of Adriamycin and daunorubicin in children. *Cancer (Phila.)*, *37*: 1070–1078, 1976.
50. Bontenbal, M., Andersson, M., Wildiers, J., Cocconi, G., Jassem, J., Paridaens, R., Rotmensz, N., Sylvester, R., Mouridsen, H. T., Klijn, J. G., and van Oosterom, A. T. Doxorubicin vs epirubicin, report of a second-line randomized Phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. *Br. J. Cancer*, *77*: 2257–2263, 1998.